G. von Minckwitz

Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).

N. Robert, M. Gnant, H. Iwata, 2015 .

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

S. Chan, T. Pintér, I. Bodrogi, 1999, Journal of Clinical Oncology.